Rigel Shares Face Pressure Despite Clinical Trial Milestone
Published on 10/10/2025 at 03:36 | Redaktion boerse-global.de
Rigel Pharmaceuticals shares are experiencing downward momentum following an important clinical development announcement. The biotechnology firm revealed it has enrolled the initial patient in the dose expansion segment of its Phase 1b trial for R289. Despite achieving this research milestone, investor sentiment has turned negative, creating a puzzling market reaction that warrants examination.
The company’s recent financial results offer substantial support for ongoing research initiatives. For the second quarter of 2025, Rigel reported:
- Net income reaching $59.6 million ($3.33 per share)
- Revenue of $101.7 million, surpassing analyst projections
- Raised annual revenue guidance to $270-$280 million
This robust financial position gives the company significant flexibility to continue advancing R289 through clinical development phases.
Market... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
